NEW YORK (GenomeWeb News) – Scientists working with the International Serious Adverse Events Consortium will use Cerner's research platform in their efforts to understand genetic risks for liver injury and hypersensitivity reactions.
The SAEC said Wednesday that under a new collaboration its researchers will use the Cerner DiscovereT web-based research platform to collect data for studies of both of these types of adverse drug reactions.
The consortium is a global partnership between pharmaceutical companies, the US Food and Drug Administration, and universities, which aims to identify and confirm genetic markers that can be used to predict which patients are at high risk for adverse reactions, and it has begun by looking into drug-induced liver injury (DILI) and hypersensitivity reactions.
The SAEC's data analysis and coordinating center is located at Columbia University, and it provides "free and unencumbered" access to study data from genetic association studies, the consortium said.
By identifying and validating genetic markers associated with drug-induced adverse events, the consortium aims to make drugs more effective, lower the costs of drug development and adverse events, and advance personalized patient care.
Cerner Life Sciences' senior VP Dick Flanigan said in a statement.
"Through Cerner Research Network we will offer our clients the opportunity to take part in this landmark collaboration," Cerner Life Sciences Senior VP Dick Flanigan said in a statement.
"Our efforts to date with DILI and Serious Skin Rash have leveraged existing academic networks recruiting research subjects across a limited number of hospitals," SAEC Chairman Arthur Holden said in a statement. "We plan to open these research studies to additional clinical sites to increase the breadth and diversity of patients who will have the opportunity to contribute to this vital research effort."